Fibrocell Science Inc (NASDAQ:FCSC)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Friday. They currently have a $5.70 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 77.85% from the company’s current price.

Several other equities research analysts have also recently issued reports on FCSC. ValuEngine cut Fibrocell Science from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Zacks Investment Research upgraded Fibrocell Science from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a report on Wednesday, July 12th. Finally, Canaccord Genuity restated a “buy” rating and set a $7.00 price objective (up previously from $3.00) on shares of Fibrocell Science in a report on Monday. Two analysts have rated the stock with a sell rating and three have issued a buy rating to the company. Fibrocell Science currently has an average rating of “Hold” and an average price target of $4.74.

Fibrocell Science (NASDAQ:FCSC) traded up 6.90% during trading on Friday, reaching $3.41. The company’s stock had a trading volume of 97,791 shares. The company’s market capitalization is $50.18 million. The company has a 50 day moving average price of $2.93 and a 200-day moving average price of $2.58. Fibrocell Science has a 52 week low of $1.57 and a 52 week high of $4.64.

Fibrocell Science (NASDAQ:FCSC) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31). Fibrocell Science had a negative return on equity of 293.07% and a negative net margin of 4,307.60%. Equities research analysts anticipate that Fibrocell Science will post ($2.17) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Fibrocell Science Inc (FCSC) Receives Buy Rating from HC Wainwright” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/15/fibrocell-science-inc-fcsc-coverage-initiated-by-analysts-at-hc-wainwright.html.

A hedge fund recently raised its stake in Fibrocell Science stock. Parametric Portfolio Associates LLC lifted its holdings in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 264.0% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 48,259 shares of the company’s stock after purchasing an additional 35,000 shares during the quarter. Parametric Portfolio Associates LLC owned about 0.33% of Fibrocell Science worth $194,000 as of its most recent SEC filing. Institutional investors and hedge funds own 54.70% of the company’s stock.

About Fibrocell Science

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.